Disease awareness or subtle product placement? Orphan diseases featured in the television series “House, M.D.” - a cross-sectional analysis

BMC Medical Ethics 21 (1):1-8 (2020)
  Copy   BIBTEX

Abstract

BackgroundApproximately 7% of the general population is affected by an orphan disease, which, in the United States, is defined as affecting fewer than 1 in 1500 people. Disease awareness is often low and time-to-diagnosis delayed. Different legislations worldwide have created incentives for pharmaceutical companies to develop drugs for orphan diseases. A journalistic article in Bloomberg Businessweek has claimed that pharmaceutical companies have tried marketing orphan drugs by placing a specific disease into the popular television series “House, M.D.” which features diagnostic journeys and was produced between 2004 and 2012. This study aimed to describe the presentation of orphan diseases in the television series “House, M.D.”, to test in an exploratory fashion the hypothesis that treatable orphan conditions are overrepresented in “House, M.D.” and to discuss whether such marketing practices may or may not be ethical.MethodsA list of all medical cases depicted in the television series “House, M.D.” was obtained and classified as orphan or non-orphan according to the Orphanet database. The ratios of orphan diseases among all diseases, such with an orphan drug designation and such with an orphan drug approval by the FDA were then compared with conservative approximations of real world conditions (chi-squared tests for equality of proportions). STROBE criteria were respected.ResultsOut of a total of n = 181 different medical diagnoses, n = 42 (23.2%) were orphan diseases. The difference in percentages in between “House, M.D.” and reality was not statistically significant for orphan diseases overall (p = 0.96), yet was statistically significantly higher for both orphan diseases with one or more orphan drug designations (p = 0.0192) and such with one or more approved orphan drugs (p < 0.0001).ConclusionsOrphan diseases with a designated and/or approved orphan drug were overrepresented in the television series “House, M.D.” with statistical significance while orphan diseases overall were not. This may be explained by (so far) undocumented efforts of pharmaceutical companies to place their orphan drugs in the television series, as described in the article in Bloomberg Businessweek. Further research is needed into marketing practices in popular and emerging media formats.

Links

PhilArchive



    Upload a copy of this work     Papers currently archived: 90,616

External links

Setup an account with your affiliations in order to access resources via your University's proxy server

Through your library

Similar books and articles

Ethical issues in funding orphan drug research and development.C. A. Gericke - 2005 - Journal of Medical Ethics 31 (3):164-168.
Ethical and social aspects on rare diseases.Dusanka Krajnovic - 2012 - Filozofija I Društvo 23 (4):32-48.
Starving Ireland, Hungry Australia: The Irish Female Orphan Emigration Scheme, 1848-1850.Emily Lieffers - 2010 - Constellations (University of Alberta Student Journal) 2 (1).
The Poetics of the Orphan in Abdelkébir Khatibi's Early Work.Matt Reeck - 2017 - Journal of French and Francophone Philosophy 25 (1):132-149.
Gender Inversions in Haywood's The Distress'd Orphan, or, Love in a Mad-house.Earla Wilputte - 1995 - Lumen: Selected Proceedings From the Canadian Society for Eighteenth-Century Studies 14:49-61.

Analytics

Added to PP
2020-03-19

Downloads
10 (#1,025,836)

6 months
1 (#1,040,386)

Historical graph of downloads
How can I increase my downloads?

Citations of this work

No citations found.

Add more citations

References found in this work

Add more references